Italian risk-sharing agreements on drugs: are they worthwhile?

Garattini, Livio; Curto, Alessandro; Vooren, Katelijne van de

doi:10.1007/s10198-014-0585-5

Cited by 61 publications

(57 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Market-access agreements can also be considered an opportunistic way for manufacturers to keep official prices high such as maintaining a common European price, 6 while granting health authorities confidential rebates, thus preventing parallel trade and undermining effective external reference pricing.…”

Section: Introductionmentioning

confidence: 99%

Market-access agreements for anti-cancer drugs

et al. 2014

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Market-access agreements for anti-cancer drugs

et al. 2014

Self Cite

View full text Add to dashboard Cite

“…For patients who experienced only the index PF during the study period, data were extracted from hospital charts for a period beginning 3.5 months before and ending 3 months after the index PF [17] (Fig. 1a).…”

Section: Methodsmentioning

confidence: 99%

Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries

Body

Acklin

Günther

et al. 2016

Journal of Bone Oncology

View full text Add to dashboard Cite

BackgroundSkeletal-related events (SREs; pathologic fracture [PF], spinal cord compression and radiation or surgery to bone) are common complications of bone metastases or bone lesions and can impose a considerable burden on patients and healthcare systems. In this study, the healthcare resource utilisation (HRU) associated with PFs in patients with bone metastases or lesions secondary to solid tumours or multiple myeloma was estimated in eight European countries.MethodsEligible patients were identified in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. HRU data were extracted from hospital charts from 3.5 months before the index PF (defined as a PF preceded by a 6.5-month period without a SRE) until 3 months after the last SRE during the study period. Changes from baseline in the number and duration of inpatient stays, number of outpatient visits and number of procedures provided were recorded.ResultsOverall, 118 patients with PFs of long bones (those longer than they are wide, e.g. the femur) and 241 patients with PFs of other bones were included. Overall, HRU was greater in patients with long bone PFs than in those with PFs of other bones. A higher proportion of patients with long bone PFs had multiple SREs (79.7%), and more of their SREs were considered to be linked (73.4%) compared with patients with PFs of other bones (51.0% and 47.2%, respectively).ConclusionThe increased number and duration of inpatient stays for PFs of long bones compared with those for PFs of other bones may be due in part to the requirement for complicated and lengthy rehabilitation in patients with long bone PFs. Implementing strategies to delay or reduce the number of PFs experienced by patients with bone metastases or lesions may therefore reduce the associated HRU and patient burden.

show abstract

“…Here we wonder whether this burden, closely related to cost containment despite claims about contributions to scientific evidence [18], could not be mainly devolved to hospital pharmacists, in line with the concept of prescription appropriateness. Once medical specialists have made their diagnosis and prescribed a drug therapy (if necessary), why not assign to public pharmacists, in respect of the central 'rules of the game' (e.g.…”

Section: Policy Implicationsmentioning

confidence: 99%